XPeng (XPEV) Q1 2026 Earnings Transcript

XPeng reported Q1 2026 revenue of RMB 13.03 billion, down 17.6% year over year and 41.4% quarter over quarter, with a net loss of RMB 1.78 billion versus net profit of RMB 380 million last quarter. Despite weak first-quarter results, management guided Q2 deliveries of 100,000-106,000 units and revenue of RMB 19.6 billion-RMB 20.8 billion, implying 50%-60% sequential growth, supported by the new GX SUV, improving mix, and accelerating overseas expansion. Gross margin held at 20.6%, while the company emphasized AI-driven product launches, robotaxi development, and humanoid robotics as longer-term growth drivers.

Analysis

The market is likely underestimating how much of this is a mix story, not a volume story. A rebound in deliveries matters, but the more important second-order effect is that XPeng is pivoting its portfolio toward higher-price, tech-loaded trims while simultaneously turning overseas sales into a larger share of mix; that combination can expand gross profit faster than headline unit growth. If management executes, the next leg of earnings revision comes less from China EV share gains and more from localization, software attach, and premium model penetration, which should also support supplier leverage on batteries, chips, and contract manufacturing.

The clearest near-term catalyst is the Q2 reset: guidance implies a sharp sequential recovery, and the market will likely focus on whether GX orders convert without margin dilution. The risk is that the premium launch appears strong at booking but softens in fulfillment if lead times stretch and price points prove too rich for the broader customer base. In that case, the stock could give back quickly because current sentiment is already leaning on a recovery narrative; a miss would hit both multiple and estimate revisions at once.

The more interesting contrarian angle is that the long-term optionality is real, but the timing is probably being over-discounted. Robotaxi and humanoid robotics are not earnings drivers for 12-24 months, yet they can justify a higher strategic valuation if management keeps showing tangible milestones; however, they also raise the probability of sustained R&D intensity and cash burn. That makes this a classic bifurcated setup: near-term equity can work on delivery momentum and overseas margin uplift, while the bear case is that heavy AI capex delays operating leverage and turns the story into a perpetual reinvestment cycle.

Key Decisions for Investors

• Long XPEV on a 1-3 month horizon into the Q2 delivery print; use a staged entry on weakness, targeting a 15-25% move if management confirms >100k deliveries and stable gross margin, with a tight stop if bookings convert poorly or commentary turns promotional.
• Buy XPEV Jan-2027 call spreads rather than outright stock to express the robotaxi/humanoid option value; risk/reward is attractive because the upside is tied to milestone-driven rerating, while downside is limited to premium if commercialization slips past 2027.
• Pair trade: long XPEV / short a basket of more China-domestic EV incumbents over the next 6-9 months to isolate the benefit from overseas mix, localization, and higher tech attach; the thesis is that international gross profit outperforms domestic volume beta.
• If already long XPEV common, hedge with short-dated calls or covered calls into the Q2 reaction to monetize event premium; the setup is vulnerable to a 'good but not good enough' print after a strong run in expectations.
• Watch for a tactical long in suppliers exposed to AI chips and battery components only if XPEV orders translate into production ramps; otherwise avoid chasing the supply chain, as the current narrative is still valuation-led rather than confirmed throughput-led.